Scarica l'app Stockscreener
56.75
1.58%
0.88
Dopo l'orario di chiusura:
56.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RVMD Giù?
Forum
Previsione
Revolution Medicines Inc Borsa (RVMD) Ultime notizie
Revolution Medicines (NASDAQ:RVMD) Sets New 1-Year HighWhat's Next? - MarketBeat
Revolution Medicines to Participate in Upcoming Investor Conferences - The Manila Times
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For - GuruFocus.com
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential - Investing.com India
Revolution Medicines' SWOT analysis: cancer drug developer's stock potential By Investing.com - Investing.com UK
Brokerage firm bumps Revolution Medicines stock PT on positive trial data - Investing.com Canada
Revolution Medicines (NASDAQ:RVMD) Given New $60.00 Price Target at Oppenheimer - Defense World
Revolution Medicines (RVMD) Set to Announce Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024 - The Manila Times
Revolution Medicines stock hits 52-week high at $51.01 - Investing.com
Revolution Medicines stock hits 52-week high at $51.01 By Investing.com - Investing.com UK
Raymond James & Associates Purchases 116,135 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
China Universal Asset Management Co. Ltd. Purchases 12,744 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines (NASDAQ:RVMD) PT Raised to $82.00 - MarketBeat
Revolution Medicines Targets Hard-to-Treat Pancreatic Cancer With Two Early-Phase Readouts - BioSpace
Revolution Medicines reports positive RMC-9805 study results - Investing.com India
Revolution Medicines reports positive RMC-9805 study results By Investing.com - Investing.com Australia
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - The Manila Times
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with - The Bakersfield Californian
Revolution Medicines Presents Initial Data from RMC-9805 - GlobeNewswire
Needham & Company LLC Reaffirms Buy Rating for Revolution Medicines (NASDAQ:RVMD) - MarketBeat
(RVMD) On The My Stocks Page - Stock Traders Daily
Revolution Medicines reports progress in pancreatic cancer study By Investing.com - Investing.com Australia
Revolution Medicines (NASDAQ:RVMD) Shares Up 3.2%Still a Buy? - MarketBeat
Revolution Medicines reports progress in pancreatic cancer study - Investing.com India
Revolution Medicines Presents Updated Data from RMC-6236 - GlobeNewswire
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma - Yahoo Finance
Head to Head Comparison: Revolution Medicines (NASDAQ:RVMD) vs. Fresh Tracks Therapeutics (NASDAQ:FRTX) - Defense World
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma - BioSpace
Revolution Medicines Announces First Patient Dosed in Phase - GlobeNewswire
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Revolution Medicines executive sells $824,804 in stock - Investing.com India
Revolution Medicines executive sells $824,804 in stock By Investing.com - Investing.com South Africa
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month HighTime to Buy? - MarketBeat
Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Insider Sells 16,666 Shares of Stock - MarketBeat
Revolution Medicines COO Margaret Horn sells $2.52m in stock - Investing.com India
Revolution Medicines COO Margaret Horn sells $2.52m in stock By Investing.com - Investing.com South Africa
Revolution Medicines CEO sells $1.51 million in stock By Investing.com - Investing.com Australia
Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 6,000 Shares - MarketBeat
Revolution Medicines CFO Jack Anders sells shares worth $502,979 - Investing.com India
Revolution Medicines CFO Jack Anders sells shares worth $502,979 By Investing.com - Investing.com Australia
Revolution Medicines' general counsel sells $301,026 in stock By Investing.com - Investing.com Canada
Revolution Medicines CEO sells $1.51 million in stock - Investing.com India
Revolution Medicines' general counsel sells $301,026 in stock - Investing.com India
AQR Capital Management LLC Purchases New Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Check Out Revolution Medicines Inc (RVMD)’s Trade Data Rather Than the Analysts’ Views - SETE News
An Analysis of Revolution Medicines Inc (RVMD)’s Potential Price Growth - Knox Daily
Trend Tracker for (RVMD) - Stock Traders Daily
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):